Survival of patients with orbital and eyelid rhabdomyosarcoma treated on Children’s Oncology Group studies from 1997 to 2013: A report from the Children’s Oncology Group

Metts J, Xue W, Gao Z, Ermoian R, Bradley JA, Arnold MA, Dasgupta R, Venkatramani R, Walterhouse D. Survival of patients with orbital and eyelid rhabdomyosarcoma treated on Children’s Oncology Group studies from 1997 to 2013: A report from the Children’s Oncology Group. Cancer. 2023 Jun 1;129(11):1735-1743. doi: 10.1002/cncr.34723. Epub 2023 Mar 1. PubMed PMID: 36857314; PubMed Central PMCID: PMC10288338.

Orbital rhabdomyosarcoma (ORMS) commonly presents as low-risk disease (stage 1, group I-III, embryonal RMS) with excellent outcome. Long-term follow-up of patients with low-risk ORMS and outcomes of less common subgroups of ORMS treated on recent Children’s Oncology Group (COG) trials have not been reported. Patients with ORMS enrolled on COG trials from 1997 to 2013 were identified. Demographic information and disease characteristics were collected. Outcomes were determined for the following subgroups: 1) low-risk ORMS, 2) resected (group I/II) low-risk ORMS, 3) non-low-risk ORMS, and 4) recurrent ORMS. Event-free survival (EFS) and overall survival (OS) were estimated using the Kaplan-Meier method.